See every side of every news story

Browser Extension

Saturday, April 19, 2025

US Edition

Subscribe Login

Israel-Hamas Conflict

Natural Disasters

Catholic Church

Artificial Intelligence

Arcutis Biotherapeutics image

News from Arcutis Biotherapeutics

News Home Page Local News Blindspot Feed International Covid-19

International North America South America Europe Asia Australia Africa

Trending Internationally Social Media WWE Baseball Donald Trump Natural Disasters

Trending in U.S.Israel-Hamas Conflict Baseball US Politics Donald Trump US Immigration

Trending in U.K.Israel-Hamas Conflict Premier League Manchester United Soccer Manchester City

Trending Topics

Social Media WWE Baseball Donald Trump Israel-Hamas Conflict

CompanyAbout History Mission Blog Testimonials Group Subscriptions Subscribe Gift Free Trial Careers Affiliates

HelpHelp Center FAQ Contact Us For Educators/Libraries Media Bias Ratings Ownership and Factuality Ratings Referral Code News Sources Topics

ToolsApp Browser Extension Daily Newsletter Blindspot Report Newsletter Burst Your Bubble Newsletter Timelines

Gift Privacy Policy Manage Cookies Terms and Conditions

© 2025 Snapwise Inc

Search Blindspot Local

News from Arcutis Biotherapeutics

Your destination for news from Arcutis Biotherapeutics. See how Arcutis Biotherapeutics’s media bias impacts the breaking news stories of today.

We’ve discovered 8 headlines written by Arcutis Biotherapeutics during the past 3 months.

Arcutis Biotherapeutics’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Arcutis Biotherapeutics’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Your destination for news from Arcutis Biotherapeutics. See how Arcutis Biotherapeutics’s media bias impacts the breaking news stories of today. We’ve discovered 8 headlines written by Arcutis Biotherapeutics during the past 3 months.

Arcutis Biotherapeutics’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Arcutis Biotherapeutics’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Arcutis Biotherapeutics

Where is Arcutis Biotherapeutics located?Arcutis Biotherapeutics's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Arcutis Biotherapeutics News

Kinaxis Inc. to Host First Quarter 2025 Financial Results Conference Call on May 8, 2025

Marriott International

Kinaxis Inc. to Host First Quarter 2025 Financial Results Conference Call on May 8, 2025

58% Center coverage: 81 sources

OTTAWA, Ontario--(BUSINESS WIRE)--Apr 16, 2025-See the Story

Arcutis Appoints Latha Vairavan as Chief Financial Officer

Westlake Village · Westlake Village

Arcutis Appoints Latha Vairavan as Chief Financial Officer

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immunodermatology, today announced that David Topper, Arcutis’ chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as C…See the Story

You've scrolled to the bottom of the feed, there are no more stories.

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - Arcutis Biotherapeutics

Maryland · Maryland

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - Arcutis Biotherapeutics

One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments including topical steroids Second poster will highlight improvements in patient-related outcomes with ZORYVE® (roflumilast) foam 0.3% in psoriasis of the scalp and body WESTLAKE VILLAGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) — Arcutis B…See the Story

FDA Accepts Roflumilast Cream sNDA in Atopic Dermatitis for Ages 2-5 Years

United States · United States

FDA Accepts Roflumilast Cream sNDA in Atopic Dermatitis for Ages 2-5 Years

On Feb. 26, 2025, Arcutis Biotherapeutics announced the FDA's acceptance of their sNDA for roflumilast cream 0.05% in AD for children aged 2 to 5 years.See the Story

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Arcutis Biotherapeutics

Westlake Village · Westlake Village

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Arcutis Biotherapeutics

WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) — Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and including a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returns Full Year 2024 net product revenue for ZORYVE was $166.5 million, an increase of 471%…See the Story

Phase 3 Trial Supports Roflumilast for Pediatric AD

Maryland · Maryland

Phase 3 Trial Supports Roflumilast for Pediatric AD

Lead author on recent research, Lawrence Eichenfield, MD, said if approved, this treatment could fill a “significant gap.”See the Story

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

Pleasanton · Pleasanton

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

83% Center coverage: 6 sources

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual…See the Story